Fulcrum Therapeutics, Inc.
FULC
$3.52
$0.082.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -100.00% | 3,087.25% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -100.00% | 3,087.25% |
| Cost of Revenue | -0.41% | -11.49% | -25.85% | -28.99% | -23.83% |
| Gross Profit | -347.07% | -437.69% | -613.78% | -816.71% | 131.77% |
| SG&A Expenses | -10.83% | -21.35% | -24.59% | -25.33% | -16.97% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -4.26% | -15.09% | -25.41% | -27.70% | -21.44% |
| Operating Income | -731.99% | -327.39% | -187.02% | -152.36% | 90.76% |
| Income Before Tax | -14,824.71% | -669.97% | -297.00% | -261.84% | 99.49% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -14,824.71% | -669.97% | -297.00% | -261.84% | 99.49% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -14,824.71% | -669.97% | -297.00% | -261.84% | 99.49% |
| EBIT | -731.99% | -327.39% | -187.02% | -152.36% | 90.76% |
| EBITDA | -853.19% | -357.10% | -200.37% | -163.20% | 91.91% |
| EPS Basic | -2,360.30% | -498.08% | -305.92% | -266.26% | 97.10% |
| Normalized Basic EPS | -8,429.76% | -618.79% | -357.99% | -256.30% | 99.16% |
| EPS Diluted | -1,484.73% | -430.77% | -278.09% | -245.79% | 95.48% |
| Normalized Diluted EPS | -3,395.12% | -543.03% | -325.95% | -236.63% | 97.96% |
| Average Basic Shares Outstanding | 10.82% | 5.34% | -2.77% | -2.62% | -2.60% |
| Average Diluted Shares Outstanding | 10.19% | 4.74% | -3.31% | -3.16% | -2.04% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |